Thank you for joining us at World Vaccine Congress 2022!
Learn more about how you can benefit from our experience and our relationships to stay two steps ahead in your vaccine development.
To achieve our vision of a world where advances in vaccines help all people live longer, healthier lives, we remain ready to deploy at a moment’s notice, regardless of geography or therapeutic area.
Proven processes to respond to the urgency and complexity of vaccine trials
Global network of research-ready investigators and sites
Partnerships with leading public and private medical research organizations, pharmaceutical and biotechnology companies, academic institutions, governments and non-governmental organizations
Leading the way in vaccine development
FHI Clinical experts are leading interactive discussions at WVC about some of the pressing topics in vaccine development, including the impact of COVID-19 on the future of vaccine development, how to find research-capable sites and representative populations and how Africa is poised to be an important research hub.
COVID-19 Vaccine Trials: Adapting to Evolving Epidemiology and Regulatory Requirements
Presented by Jon “Ben” Woods, Senior Medical Advisor
Africa: Untapped Potential for High-Quality Clinical Trials
Presented by Sanchia Theron, Global Head, Medical Affairs
Equity in Site Selection: Ensuring Inclusion of a Broad Range of Research-Capable Sites Globally
Presented by Ghiorghis (George) Belai Vice President, Global Strategy
Vaccines are critical to the eradication of infectious diseases worldwide. To achieve the FHI Clinical vision of a world where advances in vaccines help all people live longer, healthier lives, we’ve spent years honing our processes to respond to the urgency and complexity of vaccine trials, developing our global network of research-ready investigators and sites, and partnering with leading public and private medical research organizations, pharmaceutical and biotechnology companies, academic institutions, governments and non-governmental organizations.
Full-Service Global Support for COVID-19 Studies
Our broad expertise, end-to-end services and ability to begin immediate collaboration with government, commercial and academic partners in more than 60 countries make us uniquely positioned to support the COVID-19 response. We address emerging pandemics, epidemics and outbreaks with expertise that supports health and research efforts globally. We are experienced in addressing the complex aspects of infectious diseases — from infection prevention and control to clinical research on diagnostics, vaccines and treatment.
Our Experience in sub-Saharan Africa
FHI Clinical has long-standing relationships, a local team and broad expertise in sub-Saharan Africa. We're ready to help you confidently expand your research across the region, finding the best-fit countries and populations for your target indication and study type.
About the PREVAIL Network
The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network was established through a partnership between local Liberian and international partners, including the U.S. National Institutes of Health, World Health Organization and FHI Clinical, to provide sustainable research infrastructure to address diseases of public health importance.
Phase II Trial of a Chikungunya Vaccine in the Caribbean
The study team maintained a 91% retention rate in a study of a Chikungunya virus (CHIKV) vaccine, despite study disruptions due to natural disasters, including Hurricane Maria, and political unrest near the sites in five Caribbean countries in a CHIKV endemic region.
Phase II/IIb Trial of a Zika Vaccine Spanning Nine Countries
In a study conducted at 17 sites spanning nine countries in a Zika endemic region of the Americas and Caribbean, timely staffing of contract research associates (CRAs) was enabled by the project team’s network of bilingual resources and knowledge of local hiring practices.
Global Vaccine Development
To achieve our vision of a world where advances in vaccines help all people live longer, healthier lives, we’ve honed our processes to respond to the urgency and complexity of vaccine trials, developed our global network of investigators and sites, and partnered with organizations across public, private, academic and government sectors.
Africa’s Potential for Clinical Research
In this webinar, our panel of Africa-based researchers discuss the strong clinical research foundation, the community-centered approach and increasing regulatory harmonization in Africa. Watch to learn about the continent’s population diversity, expanding therapeutic area expertise and long-standing stakeholder engagement.
Follow the Epi: Finding TB-Prevalent Populations to Guide TB Vaccine Protocol Design
In this plenary discussion, experts in infectious diseases discuss how real-world epidemiology data, site capacity data and biosurveillance methodology could help identify TB-prevalent populations during protocol design, helping to ensure an adequate sample for TB vaccine development.
How Can We Streamline the Vaccine Development Process?
To address the urgency of vaccine development during a pandemic, innovative strategies are implemented across study design, regulatory processes, recruitment process and more. In this e-book, we describe some of those innovations and argue for incorporating these into the fabric of clinical trials — to establish a “new normal.”